Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors, is pleased to note that its portfolio company, Little Green Pharma Ltd ('LGP'), has published its quarterly activities report and Appendix 4C for the period ending 30 September 2024 on the ASX.

The Company owns 7,324,796 ordinary shares in LGP representing 2.43% of LGP's issued share capital.

Commenting on the announcement, Alfredo Pascual, Director of Investment Research at SEED, said: "We are delighted with LGP's remarkable recent performance, achieving record quarterly revenue of A$10.2 million and cash receipts of A$10.8 million-representing impressive growth of 40% and 30% quarter-over-quarter, respectively. The company is not only outpacing its competitors but is also generating positive cash flows from its operations. With minimal long-term debt and an improved cash position at the close of the quarter, these results highlight the strength of LGP's strategy and business model. The recent rise in LGP's share price reflects growing market recognition of its potential, and we believe there is considerable opportunity for further growth. We remain confident in LGP's ability to sustain this momentum."

Quarterly Activities Report and Appendix 4C

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to provide its activities report and Appendix 4C for the quarter ending 30 September 2024.

Highlights

• Revenue of $10.2 million (unaudited), up 40% on prior quarter.
• Cash receipts of $10.8 million, up over 30% on prior quarter.
• Net operating cash inflow of over $1.0 million resulting in cashflow positive quarter of $0.6 million.
• Cost savings of $0.5 million per year expected from subcontracting Australian cultivation operations.
• Cash in bank of $4.8 million up from $4.3 million.
• Over 30% increase in flower sales in Australia and a 35% increase in oil sales.
• Over 80% increase in European sales against prior quarter: 60% increase in flower sales into Europe with over 110% increase in French oil sales.
• Robust growth across brands:

o CherryCo sales up 50% on prior quarter.

o LGP brand sales up nearly 30% on prior quarter including sales into France, the UK and Switzerland.

o White label sales up 35% on prior quarter including sales into Australia, Germany and the UK.

o Introduction of new Indicare brand in September 2024.

The announcement in full can be accessed from the following link: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.investlittlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=0a5c8d62-8ea1-41ae-a74d-9d9018e3e1e1

Little Green Pharma

Nominated Adviser